Detalhe da pesquisa
1.
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Haematologica
; 103(7): 1218-1228, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29622655
2.
Imaging a functional tumorigenic biomarker in the transformed epithelium.
Proc Natl Acad Sci U S A
; 110(1): 93-8, 2013 Jan 02.
Artigo
Inglês
| MEDLINE | ID: mdl-23248318
3.
Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.
J Exp Med
; 219(4)2022 04 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35262628
4.
Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL.
Cancer Discov
; 11(8): 2032-2049, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33727310
5.
Integrin αvß8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy.
Cell Rep
; 36(1): 109309, 2021 07 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34233193
6.
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
Clin Cancer Res
; 26(22): 6028-6038, 2020 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32917735
7.
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
Antibodies (Basel)
; 8(4)2019 Nov 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31694242
8.
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
JCI Insight
; 3(17)2018 09 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30185663
9.
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
J Clin Invest
; 126(12): 4640-4653, 2016 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27841764
10.
Tumor detection by imaging proteolytic activity.
Cancer Res
; 70(4): 1505-12, 2010 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20145119